NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 03/15/2021 07:31
Last Report Issued 10/21/2020 13:08

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 8756B-POS
Patient ID 8756B-POS
Chain 20002050
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 20002050

Received 10/19/2020 13:29

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes Not frozen as required

Analysis and Comments	Result	Units	Reporting Limit	Notes
8756B Novel Psychoactive Substances (NPS) Screen 1, Blood				
Analysis by High Performance Liquid Chromatography/Time of Flight-Mass Spectrometry (LC/TOF-MS)				
2-Furanylfentanyl	None Detected	ng/mL	0.10	
Synonym(s): Fu-F; Furanylfentanyl				
Substance(s) known to interfere with the identity and/or quantity of the reported result: Azithromycin.				
3-Fluorophenmetrazine	None Detected	ng/mL	5.0	
Synonym(s): 3-FPM				
3-MeO-PCP	None Detected	ng/mL	5.0	
Synonym(s): 3-Methoxy-Phencyclidine				
4-ANPP	None Detected	ng/mL	0.10	
4-MeO-PCP	None Detected	ng/mL	5.0	
Synonym(s): 4-Methoxy-Phencyclidine				
25B-NBOMe	None Detected	ng/mL	1.0	
Synonym(s): 2C-B-NBOMe				
25C-NBOMe	None Detected	ng/mL	1.0	

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): 2C-C-NBOMe				
25H-NBOMe	None Detected	ng/mL	1.0	
Synonym(s): 2C-H-NBOMe				
25I-NBOMe	None Detected	ng/mL	1.0	
Synonym(s): 2C-I-NBOMe				
Acetyl Fentanyl	See Comment	ng/mL	0.50	
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				
Acryl Fentanyl	None Detected	ng/mL	0.10	
Synonym(s): Acryloylfentanyl				
Acryl fentanyl is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Alpha-Hydroxyetizolam	See Comment	ng/mL	5.0	
Comment: Based on this screening result, confirmation testing was performed. Refer to the confirmation test result(s).				
alpha-PVP	None Detected	ng/mL	2.0	
Synonym(s): alpha-Pyrrolidinovalerophenone; alpha-pyrrolidinopentiophenone				
Bromazepam	None Detected	ng/mL	10	
Butylone	None Detected	ng/mL	10	
Butyrylfentanyl	None Detected	ng/mL	0.10	
Synonym(s): Butyrfentanyl				
BZP	None Detected	ng/mL	10	
Synonym(s): 1-Benzylpiperazine				
Carfentanil	None Detected	ng/mL	0.10	
Synonym(s): Carfentanyl; Wildnil®				
cis-3-Methylfentanyl	None Detected	ng/mL	0.10	
Clephedrone	None Detected	ng/mL	50	
Synonym(s): 4-CMC; 4-chloromethcathinone				

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Clephedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Clonazolam	None Detected	ng/mL	5.0	
Cyclopropylfentanyl	None Detected	ng/mL	0.50	
Delorazepam	None Detected	ng/mL	5.0	
Synonym(s): Chlordesmethyldiazepam; Cloxazolam metabolite				
Deschloroetizolam	None Detected	ng/mL	2.0	
Dibutylone	None Detected	ng/mL	10	
Synonym(s): bk-DMBDB				
Diclazepam	None Detected	ng/mL	20	
Ethylone	None Detected	ng/mL	10	
Etizolam	None Detected	ng/mL	10	
Flubromazepam	None Detected	ng/mL	20	
Flubromazolam	None Detected	ng/mL	5.0	
Isobutyrylfentanyl	None Detected	ng/mL	0.10	
MDPV	None Detected	ng/mL	10	
Synonym(s): Methylenedioxypyrovalerone				
Meclonazepam	None Detected	ng/mL	5.0	
Mephedrone	None Detected	ng/mL	10	
Synonym(s): 4-methylmethcathinone				
Mephedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
meta-Methylmethoxyacetylfentanyl	None Detected	ng/mL	0.50	
Synonym(s): 3-Methylmethoxyacetylfentanyl				
Methoxetamine	None Detected	ng/mL	2.0	
Synonym(s): 2-MeO-Oxo-PC; MXE				
Methoxphenidine	None Detected	ng/mL	5.0	
Synonym(s): MXP				
Methoxyacetylfentanyl	None Detected	ng/mL	0.50	

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Methylone	None Detected	ng/mL	10	
Synonym(s): 3,4-methylenedioxy-N-methylcathinone; bk-MDMA				
Methylone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Mitragynine	None Detected	ng/mL	10	
Synonym(s): Kratom				
MPHP	None Detected	ng/mL	10	
Synonym(s): 4'-methyl-alpha-Pyrrolidinohexiophenone				
N-Ethyl Pentylone	None Detected	ng/mL	10	
ortho-Fluorofentanyl	None Detected	ng/mL	0.10	
para-Fluorobutyrylfentanyl	None Detected	ng/mL	0.10	
Synonym(s): 4F-butyryl fentanyl				
para-Fluorofentanyl	None Detected	ng/mL	0.10	
para-Fluoroisobutyrylfentanyl	None Detected	ng/mL	0.10	
Synonym(s): 4F-Isobutyrylfentanyl; FIBF				
para-Methylmethoxyacetylfentanyl	None Detected	ng/mL	0.50	
Synonym(s): 4-Methylmethoxyacetylfentanyl				
Pentedrone	None Detected	ng/mL	2.0	
Pentedrone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Pentylone	None Detected	ng/mL	10	
Pentylone is known to have limited stability in blood which may be dependent upon pH, collection tube, and storage temperature. Negative results should be interpreted with caution.				
Phenazepam	None Detected	ng/mL	10	
Pyrazolam	None Detected	ng/mL	5.0	
TFMPP	None Detected	ng/mL	10	
Synonym(s): 3-Trifluoromethylphenylpiperazine				
THF-F	None Detected	ng/mL	0.20	

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): Tetrahydrofuran fentanyl				
trans-3-Methylfentanyl	None Detected	ng/mL	0.10	
U-47700	None Detected	ng/mL	1.0	
Synonym(s): U-4				
U-49900	None Detected	ng/mL	1.0	
U-51754	None Detected	ng/mL	1.0	
Valeryl Fentanyl	None Detected	ng/mL	0.50	

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52486B Acetyl Fentanyl Confirmation, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Acetyl Fentanyl	None Detected	ng/mL	0.10

Acetyl fentanyl is a novel non-prescription synthetic opioid that has been implicated in several deaths. This fentanyl analog was previously undocumented in illicit drug use and is estimated to be five times more potent than heroin. Several state agencies have issued public health warnings. The Centers for Disease Control (CDC) has recommended increased vigilance by public health agencies, emergency departments, state laboratories, medical examiners, and coroners for patients with symptoms consistent with opioid overdose. It is also recommended that if a fentanyl immunoassay (e.g., ELISA) produces a positive result additional confirmation testing be performed and that this testing should include fentanyl and its analogs, including acetyl fentanyl.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

52502B Designer Benzodiazepines Confirmation 1, Blood

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Bromazepam	None Detected	ng/mL	5.0	
Bromazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries. Average peak plasma concentrations following a single 3 mg, 6 mg and 12 mg dose were reported to be 10 ng/mL at 8 hours, 83 ng/mL at 2 hours and 130 ng/mL at 1-4 hours after dosing, respectively. Chronic oral administration of 9 mg daily resulted in an steady-state plasma concentrations of 81-150 ng/mL (Average = 120 ng/mL). Reported half-lives are 12 - 27 hours. The blood to serum/plasma ratio is not known.				
Clonazolam	None Detected	ng/mL	5.0	
Clonazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country.				
Flubromazepam	None Detected	ng/mL	20	
Flubromazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country. The peak serum concentration following a single 4 mg oral dose was reported to be 78 ng/mL at 6 hours and				

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
the half-life was reported to be 106 hours. The blood to serum/plasma ratio is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Chlordiazepoxide, Midazolam.				
Etizolam	None Detected	ng/mL	2.0	
Etizolam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries. Average peak plasma concentrations following a single 0.5 mg and 1 mg dose were reported to be 8.3 ng/mL and 17 - 21 ng/mL (extensive and poor metabolizers, respectively) approximately 1 hour after dosing, respectively. Chronic oral administration of 1 mg daily resulted in an average steady-state plasma concentrations of 9.3 ng/mL. Reported half-lives are 7 - 15hours. The blood to plasma ratio is not known.				
Flubromazolam	None Detected	ng/mL	2.0	
Flubromazolam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country. A serum specimen analyzed approximately 19 hours post-ingestion of a reported 3 mg dose had a Flubromazolam concentration of 59 ng/mL. The blood to serum/plasma ratio is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Oxazepam.				
Delorazepam	None Detected	ng/mL	5.0	

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Synonym(s): Chlordesmethyldiazepam; Cloxazolam metabolite				
Delorazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries. In addition, the pharmaceutical benzodiazepine Cloxazolam is rapidly metabolized to delorazepam.				
Average peak plasma concentrations of delorazepam following a single 4 mg dose of Cloxazolam was reported to be 16 ng/mL at 2 hours and the half-life of delorazepam was reported to be 137 hours.				
The blood to plasma ratio is not known.				
Alpha-Hydroxyetizolam	5.0	ng/mL	2.0	
Alpha-hydroxyetizolam is a major metabolite of etizolam, a benzodiazepine that is prescribed in certain Asian and European countries. Etizolam is not approved for use in the United States, and is typically encountered as a novel psychoactive substance. Alpha-hydroxyetizolam has pharmacological activity nearly equal to that of etizolam and accumulates in plasma due to its longer elimination half-life, approximately twice that of its parent.				
Phenazepam	None Detected	ng/mL	20	
Phenazepam is a benzodiazepine drug that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not approved for use in the United States, but is available in some other countries.				
Average peak plasma concentrations following a single 3 mg and 5 mg dose were reported to be 24 ng/mL and				

Results for sample 20002050-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Sample ID 20002050-001
Matrix Blood
Patient Name 8756B-POS
Patient ID 8756B-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
38 ng/mL at 4 hours after dosing, respectively. The reported half-life is 60 hours. The blood to serum/plasma ratio is not known. Substance(s) known to interfere with the identity and/or quantity of the reported result: Nordiazepam.				
Diclazepam	None Detected	ng/mL	5.0	
Diclazepam is a benzodiazepine that is used as a novel psychoactive substance. It is reported to have CNS depressant properties and shares anticonvulsant, muscle relaxant, hypnotic, anxiolytic and sedative effects with other benzodiazepines. It is not marketed for use as a pharmaceutical product in any country. The peak serum concentration following a single 1 mg oral dose was reported to be approximately 3.4 ng/mL at 3 hours. Diclazepam is metabolized to the active compounds delorazepam (chlordesmethyldiazepam), lormetazepam and lorazepam. Diclazepam may be detected in serum for at least to 4 days after use. The reported half-life is 42 hours. The blood to serum/plasma ratio is not known.				

Sample receipt condition is inappropriate for test code: Not frozen as required

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.